PacBio Names New CEO, Cuts 8% of Workforce in Restructuring
PACB sits 17% above its 52-week low of $1.09 on elevated volume (1.8× avg).
Summary
PacBio appointed COO Mark Van Oene as CEO, replacing Christian Henry who remains on the board as an adviser. Simultaneously, the company announced an 8% workforce reduction (about 40 employees) as part of a restructuring expected to save $30M-$40M in annual operating expenses by end of 2027. The layoffs will incur roughly $2M in pre-tax charges in Q3. This follows a Q2 earnings miss reported earlier today, with revenue of $39M below consensus and a wider loss. The CEO transition and cost-cutting signal urgency to improve financial performance amid ongoing challenges.
At the time of this announcement, PACB was trading at $1.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $403.8M. The 52-week trading range was $1.09 to $2.73. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.